Received Nov 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | 025B21A | IM / LA |
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | 822C21A | IM / LA |
In July 2021, approximately two months after my second Moderna COVID-19 vaccination, I began experiencing severe heart palpitations, prompting me to schedule an appointment with a cardiologist. I was evaluated on August 19, 2021. All cardiac tests were normal, and the cardiologist recommended that I have my thyroid checked. I did not pursue thyroid testing at that time. In mid-September 2021, I developed significant throat pain localized to the center of my neck. I visited my primary care provider, and over the following month, underwent multiple tests for COVID-19, strep throat, and influenzaall of which were negative. Despite two rounds of antibiotics, the pain persisted. In early November 2021, I noticed enlarged lymph nodes in my neck and along my collarbone. I was referred for diagnostic imaging, including an ultrasound on November 8, a CT scan on November 10, and a biopsy on November 19. I was subsequently diagnosed with metastatic thyroid cancer. I had no prior history of thyroid disease or related symptoms before this sequence of events. My surgery lasted approximately twelve hours and was complicated by a severe chyle leak caused by a large lymph node encasing the thoracic duct. It took more than a month and multiple procedures to resolve the leak. During surgery, three of my four parathyroid glands were removed, and the remaining gland is nonfunctional, resulting in chronic hypocalcemia. Physicians expressed concern because I have no family history of this aggressive form of thyroid cancer and no known exposure to radiation. I have also never tested positive for COVID-19. I would like to reference the study My cancer presentation closely mirrors the cases described in this report. When comparing my pathology findings to those outlined in the study, the conclusion was: "The extent of lymph node involvement and extranodal extension places your cancer closer to the more aggressive profile described in this study."
None
None
None
Sulfa
11/8/21 - Ultrasound; 11/10/21 - CT Scan; 11/29/21 - biopsy